CHICAGO -- Adding perioperative durvalumab (Imfinzi) to FLOT chemotherapy significantly improved event-free survival (EFS) ...

CHICAGO -- Neoadjuvant nivolumab (Opdivo) plus chemotherapy significantly improved overall survival (OS) compared with ...

New data show improved outcomes in resectable pancreatic cancer with PAXG chemotherapy over standard mFOLFIRINOX, but should ...

[1]Versteijne E, van Dam JL, Suker M, et al. Dutch Pancreatic Cancer Group. Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer ...

Adding Imfinzi to fluorouracil-based chemo improved event-free survival and response rates in resectable gastric and ...

Neoadjuvant nivolumab monotherapy in patients with resectable gastric cancer: Preliminary results from a multicenter study. This is an ASCO Meeting Abstract from the 2021 ASCO Annual Meeting I. This ...

AstraZeneca’s immunotherapy Imfinzi has proven it can help certain patients with early-stage stomach cancer, according to ...

Adding durvalumab to perioperative FLOT improved EFS in patients with resectable gastric or GEJ cancer in the MATTERHORN ...

Efficacy and safety of serplulimab with DP induction chemotherapy followed by nimotuzumab and IMRT in locally advanced nasopharyngeal carcinoma: A retrospective study. This is an ASCO Meeting Abstract ...

Novel combination with efti has met the trial's primary endpoint of tumour hyalinization/fibrosis in the neoadjuvant setting ...

Martin Dietrich, MD, PhD, discusses how the FDA-approved combination therapy is transforming care for resectable early-stage non–small cell lung cancer (NSCLC). In this interview, Martin ...